User profiles for Magnus Gisslen
 | Magnus GisslénVerified email at infect.gu.se Cited by 16061 |
Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19
…, RW Price, K Blennow, H Zetterberg, M Gisslén - Neurology, 2020 - AAN Enterprises
Objective To test the hypothesis that coronavirus disease 2019 (COVID-19) has an impact
on the CNS by measuring plasma biomarkers of CNS injury. Methods We recruited 47 …
on the CNS by measuring plasma biomarkers of CNS injury. Methods We recruited 47 …
[HTML][HTML] Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study
M Gisslén, RW Price, U Andreasson, N Norgren… - …, 2016 - thelancet.com
Background Cerebrospinal fluid (CSF) neurofilament light chain protein (NFL) is a sensitive
marker of neuronal injury in a variety of neurodegenerative conditions, including the CNS …
marker of neuronal injury in a variety of neurodegenerative conditions, including the CNS …
Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis
…, L Forsgren, JL Frederiksen, M Gisslén… - JAMA …, 2019 - jamanetwork.com
Importance Neurofilament light protein (NfL) is elevated in cerebrospinal fluid (CSF) of a
number of neurological conditions compared with healthy controls (HC) and is a candidate …
number of neurological conditions compared with healthy controls (HC) and is a candidate …
[HTML][HTML] Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders
Background To accurately interpret COVID-19 seroprevalence surveys, knowledge of serum-IgG
responses to SARS-CoV-2 with a better understanding of patients who do not …
responses to SARS-CoV-2 with a better understanding of patients who do not …
[HTML][HTML] COVIDENZA-A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus …
…, J Styrke, J Repo, ÅÖ Balkhed, K Niward, M Gisslén… - Trials, 2021 - Springer
Objectives The main goal of the COVIDENZA trial is to evaluate if inhibition of testosterone
signalling by enzalutamide can improve the outcome of patients hospitalised for COVID-19. …
signalling by enzalutamide can improve the outcome of patients hospitalised for COVID-19. …
HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment
…, B Svennerholm, RW Price, M Gisslén - Journal of Infectious …, 2010 - academic.oup.com
Background. Occasional cases of viral escape in cerebrospinal fluid (CSF) despite suppression
of plasma human immunodeficiency virus type 1 (HIV-1) RNA have been reported. We …
of plasma human immunodeficiency virus type 1 (HIV-1) RNA have been reported. We …
[HTML][HTML] Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up
…, B Nellgård, K Blennow, H Zetterberg, M Gisslén - …, 2021 - thelancet.com
Background Neurologic manifestations are well-recognized features of coronavirus disease
2019 (COVID-19). However, the longitudinal association of biomarkers reflecting CNS …
2019 (COVID-19). However, the longitudinal association of biomarkers reflecting CNS …
[HTML][HTML] The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?
Background A substantial prevalence of mild neurocognitive disorders has been reported in
HIV, also in patients treated with combination antiretroviral therapy (cART). This includes a …
HIV, also in patients treated with combination antiretroviral therapy (cART). This includes a …
Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load
…, J Peterson, E Lee, D Fuchs, A Boschini, M Gisslén… - Aids, 2012 - journals.lww.com
Objective: To characterize HIV-infected patients with neurosymptomatic cerebrospinal fluid (CSF)‘escape’,
defined as detectable CSF HIV RNA in the setting of treatment-suppressed …
defined as detectable CSF HIV RNA in the setting of treatment-suppressed …
HIV-1 infection and cognitive impairment in the cART era: a review
With the introduction of combination antiretroviral therapy AIDS dementia complex or HIV-associated
dementia, as it was termed later, largely disappeared in clinical practice. However, …
dementia, as it was termed later, largely disappeared in clinical practice. However, …
